Jane Street’s Taysha Gene Therapies TSHA Stock Holding History

Jane Street’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$508K	Buy	113,600 +28,800	+34%	+$134K	﹤0.01%	7996
2025 Q4	$466K	Buy	84,800 +71,400	+533%	+$347K	﹤0.01%	7856
2025 Q3	$43.8K	Sell	13,400 -200	-1%	-$566	﹤0.01%	10385
2025 Q2	$31.4K	Buy	+13,600	New	+$29.5K	﹤0.01%	9280
2024 Q1	–	Sell	-11,600	Closed	-$20.5K	–	10094
2023 Q4	$20.5K	Sell	11,600 -24,700	-68%	-$49.2K	﹤0.01%	8906
2023 Q3	$115K	Buy	+36,300	New	+$67.8K	﹤0.01%	7898

Other funds holding TSHA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Jane Street's TSHA Position: Q1 2026 in Review

Jane Street sold out of Taysha Gene Therapies (TSHA) in Q1 2026, closing a stake of 163,146 shares — an estimated $759K sold.

Jane Street first reported a position in TSHA in Q3 2020 and held it in 9 quarters. The position peaked at $1.82M in Q3 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

Jane Street reported no remaining Taysha Gene Therapies position as of Q1 2026 after selling out during the quarter.
Jane Street sold 163,146 Taysha Gene Therapies shares in Q1 2026, an estimated $759K.
Jane Street first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 9 quarters.
Jane Street's Taysha Gene Therapies position peaked at $1.82M in Q3 2025.
191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.